NKD2: A Potential Drug Target and Biomarker for Chronic Pain (G85409)

Target Name: NKD2

NCBI ID: G85409

NKD2

NKD2: A Potential Drug Target and Biomarker for Chronic Pain

Non-alcoholic steatohepatitis (NASH) is a chronic autoimmune liver disease that affects millions of people worldwide. The most common cause of NASH is the obesity-related metabolic disorder, insulin resistance. Insulin resistance leads to an imbalance between insulin and glucose, resulting in the development of fat in the liver, which is the hallmark of NASH. Chronic pain is a common complication in NASH patients, affecting up to 80% of patients. The pain is usually multifocal and non-cancerous, but it can be severe and debilitating.

The pain in NASH patients is thought to be caused by the activation of immune cells, including T cells and macrophages, which release cytokines that contribute to the development of pain. NK cells, a type of immune cell that play a crucial role in fighting off infections and cancer, have been shown to be involved in the pathogenesis of NASH and chronic pain.

NKD2, a protein that is expressed in NK cells, has been identified as a potential drug target and biomarker for NASH and chronic pain. NKD2 has been shown to play a role in the regulation of pain perception and the modulation of immune cells, making it an attractive target for the development of pain medications.

NKD2 and Pain Perception

NKD2 is a protein that is expressed in NK cells, which are a type of immune cell that play a crucial role in fighting off infections and cancer. NK cells are characterized by their ability to recognize and kill infected or abnormal cells, as well as their role in regulating inflammation.

In addition to its role in immune function, NKD2 has also been shown to play a role in pain perception. NKD2 has been shown to interact with GPR117, a protein that is expressed in NK cells and is involved in pain perception. GPR117 plays a crucial role in the regulation of pain perception, as it is involved in the transduction of pain signals from the nervous system to the brain.

NKD2 and Immune Cell Regulation

NKD2 has also been shown to play a role in the regulation of immune cell function. NK cells are involved in the immune response and have been shown to play a crucial role in the regulation of inflammation. NKD2 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-alpha and IL-18, which are involved in the regulation of pain perception and the maintenance of inflammation.

In addition to its role in immune function, NKD2 has also been shown to play a role in the regulation of pain perception. NKD2 has been shown to interact with TrPV1, a protein that is expressed in immune cells and is involved in the regulation of pain perception. TrPV1 plays a crucial role in the regulation of pain perception, as it is involved in the transduction of pain signals from the nervous system to the brain.

NKD2 and Chronic Pain

The combination of NASH and chronic pain is a significant public health burden, affecting millions of people worldwide. The development of new treatments for NASH and chronic pain is a priority for the healthcare system. NKD2 has been identified as a potential drug target and biomarker for NASH and chronic pain.

NKD2 has been shown to play a role in the regulation of pain perception and the modulation of immune cells. Its role in immune function and pain perception makes it an attractive target for the development of pain medications. Additionally, NKD2 has been shown to be involved in the regulation of inflammation, which is thought to be involved in the development of chronic pain.

Conclusion

NKD2 is a protein that has been identified as a potential drug target and biomarker for NASH and chronic pain. Its role in immune function and pain perception makes it an attractive target for the development of pain medications. Further research is needed to

Protein Name: NKD Inhibitor Of WNT Signaling Pathway 2

Functions: Cell autonomous antagonist of the canonical Wnt signaling pathway. May activate a second Wnt signaling pathway that controls planar cell polarity (By similarity). Required for processing of TGFA and for targeting of TGFA to the basolateral membrane of polarized epithelial cells

The "NKD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets